Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Pockets $1.7M in NIH Funding; Cash Will Pay for Arthritis, Autism, and Cancer Research

NEW YORK, Dec. 28 (GenomeWeb News) - Perlegen Sciences has won approximately $1.7 million through four recent grants from the US National Institutes of Health, according to the NIH.


The four new grants, which the NIH said are effective as of Dec. 26, but that Perlegen had not previously disclosed, include:

  • $221,819 for studying the genetic association of rheumatoid arthritis;
  • $250,000 for studying the genetic association of autism;
  • $473,243 to study evolutionary conserved sequences in the human genome; and
  • $419,580 to perform a comprehensive mutational analysis of the "cancer genome."
The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.